Females, Aging, Metabolism, and Exercise

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to determine whether a reduction in hormones (such as occurs during menopause) causes a decrease in calories burned during physical activity. This study will also determine whether a reduction in hormones decreases calories burned while sleeping, resting, and eating and whether an exercise intervention can prevent this.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Energy Restriction and Hormones in Premenopausal Women

NCT05107804

Menstruation Disturbances Luteal Phase Defect

COMPLETED NA

Physical Activity and Basal Metabolic Rate in Postmenopausal Women

NCT01550536

Postmenopausal Metabolic Health

COMPLETED NA

Effects of Physical Training on Adipose Tissue Metabolism and Insulin Sensitivity in the Menopausal Transition Phase

NCT02076932

Menopause Insulin Resistance Body Composition, Beneficial

COMPLETED NA

Bioenergetics of Exercise-Induced Menstrual Disturbances

NCT04938622

Menstruation Disturbances Luteal Phase Defect Amenorrhea +1 more

COMPLETED NA

Exercise Training and Fat Metabolism in Postmenopausal Women

NCT05351476

Postmenopausal Symptoms Obesity Prediabetic State

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will be women who are nearing menopause based on age (42-52 y) but have normal menstrual cycles. Participants will be randomized to receive monthly injections of placebo or a study drug that reduces sex hormones (GnRH agonist) for 24 weeks. Women who receive GnRH agonist will be further randomized to no exercise or a supervised exercise program. Thus, the 3 treatment groups are: placebo, GnRH agonist, GnRH agonist+exercise. The investigators will measure changes in calories burned during physical activity, sleep, rest, and after a meal after 3 and 6 months of hormone suppression using doubly-labeled water and room calorimetry. Other measures include food intake estimated from food records; body composition measured by dual-energy x-ray absorptiometry (DXA); glucose and insulin responses to an oral glucose tolerance test; and markers of inflammation in the blood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Monthly placebo injections for 6 months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

GnRH agonist

Monthly GnRH agonist injections for 6 months

Group Type ACTIVE_COMPARATOR

GnRH agonist

Intervention Type DRUG

Drug: leuprolide acetate

Other Names:

Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months

GnRH agonist + exercise

Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention

Group Type ACTIVE_COMPARATOR

GnRH agonist

Intervention Type DRUG

Drug: leuprolide acetate

Other Names:

Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months

Supervised cardiovascular exercise

Intervention Type BEHAVIORAL

Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GnRH agonist

Drug: leuprolide acetate

Other Names:

Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months

Intervention Type DRUG

Supervised cardiovascular exercise

Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months

Intervention Type BEHAVIORAL

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Leuprolide Acetate 3.75mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy women aged 40 to 60 years
2. Are still experiencing regular menstrual cycles.
3. They must be willing to be randomized to placebo or GnRHAG therapy for 24 weeks
4. Be physically able to be randomized to participate in a programmed exercise training program.

The investigators will consent up to 132 subjects with the aim of enrolling 22 in each of the 3 groups (placebo, GnRHAG, or GnRHAG+Exercise).

Exclusion Criteria

* irregular menstrual cycles defined as 2 or more missed cycles in the previous year
* serum FSH \>25 mIU/mL measured during the first 5 days of the menstrual cycle
* on hormonal contraceptive or menopausal therapy
* positive pregnancy test
* intention to become pregnant or start hormonal contraceptive therapy during the period of study
* lactation
* known hypersensitivity to GnRH or leuprolide acetate
* score \>16 on the CESD((Center for Epidemiologic Studies Depression Scale )
* severe osteopenia or osteoporosis (i.e., proximal femur or lumbar spine t scores \< -2.0)
* abnormal vaginal bleeding
* thyroid dysfunction, defined as an ultrasensitive TSH \<0.5 or \>5.0 mU/L; volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement
* uncontrolled hypertension defined as resting systolic BP \>150 mmHg or diastolic BP\>90 mmHg; participants who do not meet these criteria at first screening will be re-evaluated, including after follow-up evaluation by the PCP with initiation or adjustment of anti-hypertensive medications
* cardiovascular disease; subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT) without follow-up evaluation; follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with interpretation by a cardiologist
* orthopedic or other problems that would interfere with participation in the exercise program
* exercising at least 30 minutes per day at a moderate to vigorous intensity most days of the week (defined as \>4 d/wk) over the past 6 months
* BMI \<40 kg/m2

Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes